IRVINGTON, N.Y., March 18, 2013 /PRNewswire/ -- Research presented by MELA Sciences, Inc. (NASDAQ: MELA) at the 71 st Annual Meeting of the American Academy of Dermatology (AAD) shows that MelaFind® can increase the melanoma detection rates of resident dermatologists when deciding to biopsy melanoma at its most curable stage. The data offers new insight into the importance of skin checks appropriately assisted with MelaFind®, as the rates of melanoma continue to rise in the United States.
The study, led by Drs. Jane A. Yoo and Darrell S. Rigel, asked 121 resident dermatologists to evaluate 24 pigmented lesions that had previously been analyzed by MelaFind®. Biopsy performance results were compared before and after using the MelaFind® "High" or "Low" Disorganization score. Prior to factoring in results from MelaFind®, dermatology residents' biopsy sensitivity was 57%. After reviewing MelaFind® results, sensitivity improved to 77%. The results, combined with data from a similar study of attending dermatologists, showed that utilizing MelaFind® can significantly improve the melanoma detection rates of dermatologists at any experience level.Skin cancer rates continue to rise, while many other cancer rates decline. 1 "Only 24% of American adults have had a skin check with a dermatologist. 2 We want to increase those numbers to help combat melanoma, which has reached epidemic proportions, with one American dying every hour, 3" said Dr. Joseph Gulfo, President and CEO of MELA Sciences, Inc. "The data presented at AAD reinforces the importance of MelaFind® and how the tool helps dermatologists detect melanoma at its most curable stage." "The data demonstrates that MelaFind® increases the performance of dermatologists in their decision whether to biopsy melanoma at its most curable stage," said Darrell S. Rigel, MD, Clinical Professor of Dermatology, New York University. "MelaFind® continues to prove itself to be a worthy diagnostic tool for dermatologists to implement during skin cancer checks." MELA Sciences, Inc. is the pioneer company that developed MelaFind®, the first and only FDA-approved diagnostic tool to detect melanoma at its most curable stage. MelaFind® sees 2.5 mm under the skin and uses multi-spectral light technology to provide dermatologists with additional information of a "High" or "Low" Disorganization score when deciding which ambiguous moles to biopsy during skin examinations. In the MelaFind® Pivotal Trial, which was the largest positive prospective clinical study ever conducted in melanoma detection, MelaFind® detected 98.3% of the melanomas.